Abstract:Experimentalallergic encephalomyelitis(EAE) is an animal model for inflammatory demyelinating autoimmune disease, i.e., multiple sclerosis (MS). In the present study, we investigated the antineuroinflammatory/neuroprotective effects of C16, an alpha upsilon beta 3 integrin-binding peptide, and recombinant rat ciliary neurotrophic factor (CNTF), a cytokine that was originally identified as a survival factor for neurons, in an acute rodent EAE model. In this model, C16 peptide was injected intravenously every day for 2 weeks, and CNTF was delivered into the cerebral ventricles with Alzet miniosmotic pumps. Disease severity was assessed weekly using a scale ranging from 0 to 5. Multiple histological and molecular biological assays were employed to assess inflammation, axonal loss, neuronal apoptosis, white matter demyelination, and gliosis in the brain and spinal cord of different groups. Our results showed that the EAE induced rats revealed a significant increase in inflammatory cells infiltration, while C16 treatment could inhibit the infiltration of leukocytes and macrophages down to 2/3-1/3 of vehicle treated EAE control (P < 0.05). The delayed onset of disease, reduced clinical score (P < 0.01) in peak stage and more rapid recovery also were achieved in C16 treated group. Besides impairing inflammation, CNTF treatment also exerted direct neuroprotective effects, decreasing demyelination and axon loss score (P < 0.05 versus vehicle treated EAE control), and reducing the neuronal death from 40 to 50% to 10 to 20% (P < 0.05). Both treatments suppressed the expression of cytokine tumor necrosis factor-alpha and interferon-gamma when compared with the vehicle control (P < 0.05). Combined treatment with C16 and CNTF produced more obvious functional recovery and neuroprotective effects than individually treatment (P < 0.05). These results suggested that combination treatment with C16 and CNTF, which target different neuroprotection pathways, may be an effective therapeutic alternative to traditional therapy.

Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats

Combined Nasal Administration of Encephalitogenic Myelin Basic Protein Peptide 68–86 and IL-10 Suppressed Incipient Experimental Allergic Encephalomyelitis in Lewis Rats

The Complexity of Cytokine Treatment in Ongoing EAE Induced with MBP Peptide 68–86 in Lewis Rats

Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA.

Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

Nasal Tolerance to Experimental Autoimmune Myasthenia Gravis: Tolerance Reversal by Nasal Administration of Minute Amounts of Interferon-Gamma

SIN-1, a Nitric Oxide Donor, Ameliorates Experimental Allergic Encephalomyelitis in Lewis Rats in the Incipient Phase: the Importance of the Time Window

Long-Term Effects of IFN-γ, IL-10, and TGF-β-Modulated Dendritic Cells on Immune Response in Lewis Rats

Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells.

Therapeutic Potential Of Ifn-Gamma-Modified Dendritic Cells In Acute And Chronic Experimental Allergic Encephalomyelitis

TGF-β1 Inhibits Protracted-relapsing Experimental Autoimmune Encephalomyelitis by Activating Dendritic Cells

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

Cd8 Alpha+ Dendritic Cells And Immune Protection From Experimental Allergic Encephalomyelitis

The downregulation of specific T lymphocyte responses by nasal administration of AChR in EAMG rats

Therapeutic potential of IFN- -modified dendritic cells in acute and chronic experimental allergic encephalomyelitis

IL-10 controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation

Intranasal Delivery of Neural Stem Cells: A CNS-specific, Non-invasive Cell-based Therapy for Experimental Autoimmune Encephalomyelitis.

Nasal Delivery of Fasudil-modified Immune Cells Exhibits Therapeutic Potential in Experimental Autoimmune Encephalomyelitis.

The Limitation of IL-10-exposed Dendritic Cells in the Treatment of Experimental Autoimmune Myasthenia Gravis and Myasthenia Gravis

Suppression of Experimental Autoimmune Myasthenia Gravis by Nasal Administration of Acetylcholine Receptor